Lu-177 CTR-FAPI for advanced digestive cancers
Part of Cancer clinical trials.
This trial tests a new radioactive drug that targets a protein called FAP on cancer cells. It is for people with advanced stomach, pancreas, colon, bile duct, or esophageal cancers that have spread and show high FAP levels on a special scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is advanced or has spread and at least one tumor can be measured on a scan.
- You have a type of digestive cancer like stomach, pancreas, colon, bile duct, or esophageal cancer that shows high FAP on a special PET scan.
- You are in fairly good health with adequate kidney, liver, and blood cell counts.
- You have not had certain other cancer treatments within the last 4 to 12 weeks.
- You are willing to use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests a radioactive drug called 177Lu-JH04 for people whose tumors have high levels of a protein called FAP. The drug targets and treats advanced tumors that have stopped responding to other treatments.
This trial tests a new radioactive treatment (177Lu-FAP-2286) for people with advanced bladder cancer that has stopped responding to other therapies. It aims to see if this treatment can shrink tumors and how safe it is.
This trial is testing a new imaging method called FAPI-PET to see if it can help find and understand tumors better than standard scans. It is for people with newly diagnosed stomach/esophageal cancer, pancreatic cancer, or those with unclear symptoms or scan results.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.